Europe Point of Care (PoC) Diagnostics Market Analysis with Growth Factors, 2026-2034
REPORT DETAILS
Europe Point of Care (PoC) Diagnostics Market Summary
The Europe point of care (PoC) diagnostics market size was valued at USD 4.82 billion in 2025. The market is projected to grow at a CAGR of 10.1% from 2026 to 2034. Key factors driving demand include the rising shift towards self-testing, supportive government policies, and healthcare investment. The market expansion is also driven by the rise in the geriatric population and the increasing need for chronic disease management.
Market Statistics
Key Takeaways
- Germany accounted for 24.8% revenue share in 2025. This is due to the increasing adoption of advanced diagnostic technologies, a well-established healthcare infrastructure, and strong reimbursement support for point-of-care testing.
- The UK is expected to witness the fastest growth at a 11.6% CAGR during the forecast period. The market growth in the country is driven by increasing interest in home-testing solutions, expanding digital healthcare services, and rising awareness of preventive diagnostics.
- Infectious diseases held the largest share of 32.4% in 2025. This is due to the need for rapid and accurate diagnostic solutions to control disease outbreaks and improve timely clinical decision-making.
- The over-the-counter (OTC) segment is expected to grow at a 11.9% CAGR. The segment’s growth is driven by a clear consumer shift toward home-based healthcare, self-testing, and convenient diagnostic solutions.
- Clinics held a 37.9% revenue share in 2025. This is owing to the high demand for fast, affordable outpatient diagnostic services and the increasing adoption of point-of-care testing in primary care settings..
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Europe's increasing elderly population is prone to chronic diseases, such as diabetes, requiring regular monitoring, further increasing demand for point-of-care diagnostics.
- Technological advances are making PoC devices more user-friendly and facilitating their incorporation.
- The new EU IVDR regulation creates very expensive and difficult barriers to better access and compliance with the new regulations.
- The rising need for rapid AMR testing at the PoC represents a major driver for innovation and revenue expansion.
AI Impact on Europe Point of Care (PoC) Diagnostics Market
- AI algorithms analyze complex data to improve the precision of test results, reducing human error and supporting more reliable diagnoses at the point of care.
- AI accelerates analysis, delivering critical insights in minutes rather than hours and enabling immediate clinical decision-making, by automating data interpretation.
- AI identify patterns and trends, enabling early detection of outbreaks or antimicrobial resistance and transforming PoC devices into proactive health tools.
Point of care (PoC) diagnostics are medical tests performed at or near the patient’s location, rather than in a laboratory for timely and accurate diagnostic results. The market in Europe is driven by the rising shift towards self-testing as the patients are increasingly in need for timely diagnostic, accessible, and convenient options which help them with regular monitoring of health. This shift is further supported by the rising demand for self-based testing kits, which helps in reducing the burden on healthcare providers, reducing waiting time for reports, and provide autonomy to the consumers. Self-based tests focus on early detection of disease, by providing diagnostics closer to the patients reach, highlighting the regular support to the patients.
-diagnostics-market-size,-by-country-2020---2034.webp)
Source: Polaris Market Research Analysis
The Europe PoC diagnostics market is further driven by the supportive government policies. European government policies are promoting initiatives to support faster diagnostics to improve patient outcomes, and boost healthcare infrastructure. For instance, in March 2025, the EU4Health stated that the EU is aiming for the development of rapid, less than one hour PoC testing devices for antimicrobial testing and for the identification of bacterial or fungal disease causing infections.
Moreover, rising funding initiatives, supportive reimbursement policies and frameworks that support integrating the innovative technologies into routine monitoring have boosted the adoption of the PoC diagnostics. According to a July 2023 report from the European Union, HERA invest granted approximately USD 106 million under the InvestEU program. This funding supports the development and scaling of refined solutions such as medicinal products, diagnostic, medical device, and others, highlighting the government role in supporting the PoC testing in Europe.
Drivers & Opportunities
Growing Geriatric Population and Chronic Disease Management: The rise in geriatric population and increasing need for chronic disease management is boosting the PoC diagnostics market in Europe. Aging people are more prone to the conditions such as diabetes, cardiovascular diseases, and respiratory problems, which requires regular and timely monitoring. According to a January 2024 European Union data, 21.6% that is one fifth of Europe’s population was aged 65 years and over, stating the rising need for reliable PoC devices for timely monitoring. PoC diagnostic allow for better management of disease which consequently reduce the dependency of hospital testing and visits. This is particularly evident in the management of long term chronic conditions where continuous monitoring and quick decision making is crucial. A July 2025, European Union data stated that more than 35.3% that is one third of the Europe population had a long standing chronic problem in 2024. Therefore, by addressing the needs of aging population PoC diagnostic are improving the quality and reducing the pressure on healthcare environments.
Rising Advancement and Innovation in PoC Technology: Rising advances in PoC technologies such as integration of novel sensor, digital health platforms, miniaturization, and other advancements support the rising demand for PoC diagnostics and making it user-friendly. For example, in May 2025, Neoul launched miLab BCM an AI-powered PoC device that integrate blood morphology analysis and complete blood count (CBC) to deliver rapid diagnostic results from a blood sample into an automated system. These innovations expand the area of conditions that can be monitored and are accessible across healthcare environments. Furthermore, the integration of data sharing capabilities and connectivity features also supports the remote monitoring and patient focused care. Therefore, by offering technological driven, faster and precise solutions are boosting the growth opportunities for the PoC diagnostics.
EU Regulations Impacting Market Growth
European regulatory measures contribute to improving the safety and quality of diagnostics products. The requirements set forth by in vitro diagnostic regulations of the European Union stipulate higher demands concerning testing and assessment of products' performance. This ensures the safety and accuracy of the diagnostic products utilized. Despite increasing production costs and development time, such demands prove to be beneficial for ensuring quality and transparency. They contribute to enhancing trust in diagnostics and developing the European POC diagnostics market.
Challenges in Europe PoC Diagnostics Market
There are various challenges faced by the Europe point of care diagnostics market, such as regulations, high cost of equipment and setup, and different payment policies in the countries. In addition to this, there might be issues for hospitals and clinics integrating such equipment into their digital healthcare system.
-diagnostics-market-size-worth-usd-13.61-billion-by-2034.webp)
Source: Polaris Market Research Analysis
Segmental Insights
Product Analysis
Based on product, the segmentation includes glucose testing, Hb1Ac testing, coagulation, fertility, infectious diseases, cardiac markers, thyroid stimulating hormone, hematology, primary care systems, decentralized clinical chemistry, feces, lipid testing, cancer marker, blood gas/electrolytes, ambulatory chemistry, drug abuse testing, and urinalysis. The infectious diseases segment accounted for 32.4% revenue share in 2025 driven by the increasing infectious disease case and the need for accurate, rapid, and accessible solution to control the spread of disease. The PoC diagnostic offers rapid results for early detection and timely treatment decisions which makes them a preferred option for consumers as well as healthcare providers. Moreover, the rising focus on the demand for efficient diagnostics method integrated with preventive care has further supported the expansion of the PoC diagnostics.
Mode of Prescription Analysis
In terms of mode of prescription, the segmentation includes OTC and prescription-based. The prescription-based segment dominated the market share in 2025 driven by the need for physician testing for complex and high risk conditions. The prescription-based diagnostics provide greater accuracy, following of clinical protocols, and proper understanding of results by professionals which are essential in chronic disease management and hospital based environments. Furthermore, the involvement of professional also build trust and promote wider adoption of if these tests in clinical settings. Therefore, prescription-based diagnostics support quality and safety in medical testing.
The OTC segment is expected to witness significant growth at a CAGR of 11.9% during the forecast period due to the rising shift towards home-based healthcare, and self-monitoring. The rising focus on personal health management, increasing consumer awareness, and availability of user-friendly diagnostic kits are boosting the expansion of OTC. The OTC PoC diagnostics provide individuals privacy, autonomy, and convenience in managing their health for conditions such as infectious disease, glucose monitoring, and other diseases. Thus, the broader shift towards patient-centric and preventive care contributes to the expansion opportunities.
End Use Analysis
Based on end use, the segmentation includes, clinics, hospitals, home, assisted living healthcare facilities, and laboratory. The clinics segment held 37.97% share of the market in 2025 due to the increasing demand for cost effective, fast and reliable diagnostic services which is offered in outpatient and patient care environments. Clinics are the crucial access points for patients who are in need for immediate and rapid testing without the need for hospital visit, improving care delivery and reducing waiting time. Furthermore, clinics have the ability to integrate PoC diagnostics to support timely intervention, enhance routine practice efficiency, and manage patient satisfaction. Therefore, clinics hold a major role in shaping the utilization and growth of PoC diagnostics.
-diagnostics-market-by-product-analysis,-2020---2034.webp)
Source: Polaris Market Research Analysis
Country Analysis
Germany Point of Care (PoC) Diagnostics Market
The Germany PoC diagnostics market accounted for 24.8% revenue share in 2025 driven by increasing adoption of diagnostic technologies and rising healthcare infrastructure. Europe has a high focus on efficiency and precision in healthcare delivery, which has boosted the demand for rapid testing solutions in hospitals, clinics, and home-based monitoring. According to a November 2024 European Union report, Germany accounted for 12.6% of current healthcare expenditure that is the highest amongst all countries in Europe. The growing awareness on chronic disease and healthcare management further contributes to the PoC diagnostics. Moreover, the rising innovation in testing platform and integration into the clinical workflows improve both patient outcomes and accessibility, supporting the Germany market growth.
UK Point of Care (PoC) Diagnostics Market
The UK market is expected to witness fastest growth at a CAGR of 11.6% during the forecast period attributed to the increasing demand for adoption of home-based testing solutions and decentralized healthcare settings. The UK healthcare system focus on early intervention of disease and patient centric solutions which is driving the reliance on rapid diagnostic tools and provide immediate test results. Moreover, strong focus on integration of digital health with growing consumer acceptance of self-testing is also contributing to the expansion of UK market. Therefore, as healthcare delivery in the UK continue to evolve, PoC diagnostics is expected to witness significant growth in the country.
-diagnostics-market-country-insights,-2020-–-2034.webp)
Source: Polaris Market Research Analysis
Key Players & Competitive Analysis Report
The European PoC diagnostics landscape is influenced by competitive intelligence and strategy involving expense by small to medium businesses. Vendor strategies will take account of significant investment into new technology, credits to AI, to drive revenue stream sustainability forward. There will also be disruptions and trends that indicate substantial and encouraging expansion opportunities building off a drive for rapid antimicrobial resistance testing. The experts' perspectives suggest business models will continue their evolution, and navigation of technology, regulatory and climate change will be critical to competitive positioning and unlocking any potential latent demand and opportunities both across and within developed and emerging market segments.
Major companies operating in the Europe point of care (PoC) diagnostics industry include bioMérieux; Boditech Med Inc.; EKF Diagnostics; Grifols; HORIBA, Ltd.; Nova Biomedical; Qiagen; Roche Diagnostics; Siemens Healthineers; and Werfen.
Key Players
- bioMérieux
- Boditech Med Inc.
- EKF Diagnostics
- Grifols
- HORIBA Medical / HORIBA ABX SAS
- Nova Biomedical / Nova Biomedical EMEA
- Qiagen
- Roche Diagnostics
- Siemens Healthineers
- Werfen
Future Outlook
It is anticipated that the Europe point-of-care diagnostics market will witness a consistent growth in the years to come due to the increasing adoption of fast and effective tests by healthcare organizations. Increasing need for home testing, management of chronic diseases, and technological advancements will fuel the growth of this market. Although meeting regulatory requirements might present some hurdles, innovations in molecular diagnostics, digital health, and connected point-of-care devices can provide new avenues to growth. Germany and the United Kingdom are predicted to emerge as key markets in this region.
Industry Developments
-
March 2026: Abbott announced the completion of the acquisition of f Exact Sciences. According to Abbott, the acquisition will help enhance its position in the rapidly growing cancer screening and diagnostics segments. (source: abbott.mediaroom.com)
-
December 2025: The EU Health Technology Assessment Coordination Group (HTACG) announced the advancement of its 2026 work program. The group initiated its first-ever Joint Clinical Assessments (JCAs) for selected high-risk medical devices and in vitro diagnostic devices (IVDs). (source: ec.europa.eu)
Europe Point of Care (PoC) Diagnostics Market Segmentation
By Product Outlook (Revenue, USD Billion, 2021–2034)
- Glucose Testing
- Hb1Ac Testing
- Coagulation
- Fertility
- Infectious Diseases
- HIV
- Clostridium Difficile
- HBV
- Pneumonia or Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV)
- HPV
- Influenza/Flu
- HCV
- MRSA
- TB and Drug-Resistant TB
- HSV
- Others
- Cardiac Markers
- Thyroid Stimulating Hormone
- Hematology
- Primary Care Systems
- Decentralized Clinical Chemistry
- Feces
- Lipid Testing
- Cancer Marker
- Blood Gas/Electrolytes
- Ambulatory Chemistry
- Drug Abuse Testing
- Urinalysis
By Mode of Prescription (Revenue, USD Billion, 2021–2034)
- OTC
- Prescription-based
By End Use Outlook (Revenue, USD Billion, 2021–2034)
- Clinics
- Physician Office
- Pharmacy & Retail Clinics
- Non-practice Clinics
- Urgent Care Clinic
- Hospitals
- Home
- Assisted Living Healthcare Facilities
- Laboratory
By Country Outlook (Revenue, USD Billion, 2021–2034)
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
Europe Point of Care (PoC) Diagnostics Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 4.82 Billion |
| Market Size in 2026 | USD 5.30 Billion |
| Revenue Forecast by 2034 | USD 11.48 Billion |
| CAGR | 10.1% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Country Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Europe Point of Care (PoC) Diagnostics Market FAQ's
The market size was valued at USD 4.82 billion in 2025 and is projected to grow to USD 11.48 billion by 2034.
The market is projected to register a CAGR of 10.1% during the forecast period.
The Germany PoC diagnostics market accounted for 24.8% revenue share in 2025.
A few of the key players in the market are include bioMérieux; Boditech Med Inc.; EKF Diagnostics; Grifols; HORIBA, Ltd.; Nova Biomedical; Qiagen; Roche Diagnostics; Siemens Healthineers; and Werfen.
The infectious diseases segment accounted for 32.4% revenue share in 2025.
The prescription-based segment dominated the market revenue share in 2025.
Download Sample Report of Europe Point of Care (PoC) Diagnostics Market
Please fill out the form to request a customized copy of the research report.
